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peptide-1: a case report
Filip K Knop1,3*†, Asger Lund1†, Sten Madsbad2, Jens J Holst3, Thure Krarup4 and Tina Vilsbøll1Abstract
Background: The gut-derived incretin hormones, glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1, are released in response to ingestion of nutrients. Both hormones are highly insulinotropic in strictly
glucose-dependent fashions and glucagon-like peptide-1 is often referred to as one of the most insulinotropic
substances known.
Case presentation: Plasma insulin and C-peptide concentrations were measured in a healthy Caucasian male (age:
53 years; body mass index: 28.6 kg/m2; fasting plasma glucose: 5.7 mM; 2 h plasma glucose value following 75 g-oral
glucose tolerance test: 3.5 mM; glycated haemoglobin A1c: 5.5%) during glucagon (1 mg) and meal (2,370 kJ) tests,
and during two 2 h 15 mM-hyperglycaemic clamps with continuous intravenous infusion of glucagon-like peptide-1
(1 pmol/kg/min) and glucose-dependent insulinotropic polypeptide (4 pmol/kg/min), respectively. Normal insulin and
C-peptide responses were observed during meal test (peak concentrations: 300 and 3,278 pM) and glucagon test (peak
concentrations: 250 and 2,483 pM). During the hyperglycaemic clamp with continuous intravenous infusion of GLP-1
the subject exhibited plasma insulin and C-peptide concentrations of 13,770 and 22,380 pM, respectively.
Conclusions: To our knowledge insulin and C-peptide concentrations of these magnitudes have never been reported.
Thus, the present data support the view that glucagon-like peptide-1 is one of the most insulinotropic substances known.
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(GIP), InsulinBackground
The two incretin hormones, glucose-dependent insulino-
tropic polypeptide (GIP) and glucagon-like peptide-1
(GLP-1), are secreted from endocrine mucosal cells in
the gastrointestinal tract (K and L cells, respectively) in
response to ingestion of nutrients. Both hormones are
insulinotropic in strictly glucose-dependent fashions [1].
A priori, the insulinotropic actions of GIP and GLP-1
would be expected to be similar: The receptors of the
two incretin hormones are closely related and belong to
the same branch of the superfamily of type 2 G protein-* Correspondence: filipknop@dadlnet.dk
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unless otherwise stated.coupled receptors [2], and, furthermore, both receptors
couple to adenylate cyclase and their insulinotropic
actions depend to a large extent on the intracellular
accumulation of cyclic AMP (cAMP). Additionally, exogen-
ously delivered GIP and GLP-1 have been found to be
equally insulinotropic at physiological plasma concentra-
tions and to contribute equally to the incretin effect in
healthy subjects [3]. However, physiological plasma concen-
trations of GIP are 2 to 5 fold higher compared to GLP-1
concentrations (during fasting conditions and in the post-
prandial state). Therefore, GLP-1 has often been cited as
one of the most insulinotropic substances known [1,4-7].
Here we present a case of unprecedented high insulin
and C-peptide responses in a healthy subject following
intravenous (iv) administration of GLP-1 and discuss the
existing literature on maximal beta cell secretory response
tests and on mechanisms underlying the insulinotropic
effects of the incretin hormones.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Subject
A healthy male Caucasian (age: 53 years; body weight:
90.7 kg; body mass index: 28.6 kg/m2) with normal
glucose homeostasis (fasting plasma glucose: 5.9 mM;
2 h plasma glucose value following 75 g-oral glucose
tolerance test: 3.5 mM; glycated haemoglobin A1c: 5.5%)
and without any family history of diabetes was examined.
Insulin resistance according to the homeostasis model
assessment [8] was 1.65. He had no significant past
medical history, took no medication and clinical examin-
ation was normal. All standard investigations including
blood pressure and standard biochemical parameters in
urine and blood were normal. He agreed to participate
(verbal and written consent) after receiving oral and
written information. The examinations were approved
by the Scientific-Ethical Committee of the County of
Copenhagen (journal no.: KA 97196 m) and conducted
according to the principles of the Helsinki Declaration II.
Methods
The subject participated in a study evaluating the insuli-
notropic power of supra-physiological doses of GLP-1 as
compared to glucagon, GIP, and physiological conditions
in healthy subjects [9]. He was examined on 4 different
days (day 1 through 4) separated by minimum 48 hours.
On each occasion the subject was studied after a 10 h-fast,
including liquids, with a cannula inserted in a dorsal hand
vein for collection of blood samples. On day 2, 3 and 4,
another cannula was inserted into the contra-lateral
cubital vein for infusion of glucagon (day 2) and glucose
plus incretin hormones (day 3 and 4).
Meal test (day 1)
Blood was drawn regularly after a standard breakfast
meal ingested during 15 min. The meal comprised
2,370 kJ (566 kcal) and was composed of 34% fat, 47%
carbohydrate, and 19% protein.
Glucagon test (day 2)
Blood was sampled 15, 10 and 0 min before and 2, 3, 4,
6, 8, 10, 15, 20, 30, 45 min after iv bolus of 1 mg
(=287 nmol) biosynthetic glucagon (GlucaGen, Novo
Nordisk, Bagsværd, Denmark) in 1 ml of sterile water.
Hyperglycaemic clamps + GLP-1 (day 3) or GIP (day 4)
At time 0 min, a bolus of 50% glucose (w/v) was infused
during 1 min to increase plasma glucose to 15 mM.
Plasma glucose was kept at 15 mM by continuous infusion
of glucose, which was adjusted every 5 min according to
bedside measurements of plasma glucose. After 3 min, a
continuous infusion of 1 pmol GLP-1/kg/min (day 3)
or 4 pmol GIP/kg/min (day 4) was initiated. Blood was
sampled 15, 10 and 0 min before and 5, 10, 15, 20, 25,30, 45, 60, 75, 90, 105 and 120 min after elevation of
plasma glucose.
An additional experimental day consisting of a 2 h
15 mM-hyperglycaemic clamp with continuous infusion
of saline was designed in order to evaluate the insulin
response to hyperglycaemia without incretin hormone
infusion. However, the subject withdrew his consent due
to the symptoms of hypoglycaemia experienced follow-
ing termination of the hyperglycaemic clamp with infu-
sion of GLP-1 (see below). Thus, we found it unethical
to utilize the present design in further evaluations of
beta cell function in healthy subjects [9].
On all experimental days, blood was sampled into tubes
containing heparin or EDTA (6 mM) plus aprotinin (500
KIU/ml blood; Trasylol, Bayer, Leverkusen, Germany)
and a specific dipeptidyl peptidase 4 (DPP-4) inhibitor
(valine-pyrrolidide; 0.01 mM, final concentration; a gift
from Novo Nordisk A/S Bagsværd, Denmark) for hormone
analyses. These tubes were immediately cooled on ice and
centrifuged for 20 min at 1,200 g and 4°C. Plasma was
stored at −20°C until analysis. For bedside measurements
of plasma glucose, blood was distributed into fluoride tubes
and centrifuged immediately for 2 min at 7,400 g and room
temperature.
Analyses
Plasma glucose concentrations were measured during the
experiments by the glucose oxidase method (Yellow
Springs Instrument Model YSI 2300 STAT plus analyzer;
YSI Inc., Yellow Springs, Ohio, USA).
Plasma samples were assayed for total GLP-1 immu-
noreactivity using antiserum no. 89390, which is specific
for the C-terminal of the GLP-1 molecule and reacts
equally with intact GLP-1 and the primary (N-terminally
truncated) metabolite.
Total GIP was measured using the C-terminally directed
antiserum R65, which reacts fully with intact GIP and the
N-terminally truncated metabolite.
Plasma insulin concentrations were measured using
commercial ELISA kits (Dako, Copenhagen, Denmark).
Plasma C-peptide concentrations were determined as
described by Heding et al. [10] employing the polyclonal
antibody M1230.
Calculations and statistics
Area under the curve (AUC) values were calculated




No difference in fasting plasma glucose between the 4
experimental days was observed (average fasting plasma
glucose: 5.7 mM). Time courses for plasma glucose
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meal test plasma glucose increased to a peak value of
7.6 mM 45 min following meal ingestion. On day 2 a
peak value of 8.6 mM was observed 20 min after injec-
tion of glucagon. During the two 2 h hyperglycaemic
clamps plasma glucose was elevated to 16.4 mM (GLP-1
clamp) and 14.8 mM (GIP clamp) using 60 ml 50% (w/v)
glucose and maintained at mean concentrations of
14.8 mM (range: 12.2-17.6 mM) and 14.6 mM (range:
13.3-17.2 mM), respectively, using a total of 287 g and
287 g of glucose. Following termination of the GLP-1
clamp, plasma glucose concentrations dropped to
below 3 mM within minutes and remained here forFigure 1 Meal test and glucagon test. Plasma glucose (upper panels), in
meal test and glucagon test in a healthy subject with normal glucose tolerapproximately 1 h in spite of juice and food ingestion.
In this period the subject experienced typical symptoms
of hypoglycaemia.GLP-1 and GIP
During the meal test basal levels of plasma GLP-1 (9 pM)
rose to a peak concentration of 19 pM 90 min following
initiation of ingestion and returned to basal levels at the
end of the meal test (180 min). Basal levels of plasma GIP
(6 pM) exhibited a more brisk rise in response to meal
ingestion and peak concentration of 145 pM was attained
after 30 min (data not shown).sulin (mid panels) and C-peptide (lower panels) concentrations during
ance.
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Time courses of plasma insulin and plasma C-peptide
responses during day 1 and 2 are presented in Figure 1.
No difference in fasting plasma concentrations between
day 1 and 2 was observed. As illustrated in Figure 1 the
subject responded with normal insulin and C-peptide
responses during day 1 (meal test) and day 2 (glucagon
test); during day 1, peak concentrations (insulin: 300 pM;
C-peptide: 3,278 pM) were attained 45 min following initi-
ation of meal ingestion. During day 2, peak concentrations
of 250 pM and 2,483 pM for insulin and C-peptide,
respectively, were observed 6 and 3 min following iv
injection of glucagon.Figure 2 Hyperglycaemic clamps with GLP-1/GIP. Plasma glucose (uppe
with normal glucose tolerance during hyperglycaemic clamps with continuou
dependent insulinotropic polypeptide (open triangles), respectively. The insert
initial 15 min of the two clamps.During the 15 mM-hyperglycaemic clamp with con-
tinuous iv infusion of GIP, plasma insulin concentrations
increased from a baseline level of 48 pM to a plateau
level of 1,163 pM (range: 1,080-1,432 pM (60–120 min))
(AUC0–120 min: 104; AUC0–10 min: 2.8; and AUC10–120 min:
101 nM×min) (Figure 2).
During the hyperglycaemic clamp with continuous iv
infusion of GLP-1, plasma insulin concentrations in-
creased almost exponentially from a baseline level of 35
pM to 13,770 pM at the termination of the 2 h clamp
(AUC0–120 min: 580; AUC0–10 min: 2.5; and AUC10–120 min:
577 nM×min) (Figure 2). Plasma C-peptide concentra-
tions increased from a baseline of 700 pM to 22,380 pM.r panel) and insulin (lower panel) concentrations in a healthy subject
s infusion of glucagon-like peptide-1 (filled triangles) and glucose-
in the lower panel illustrates plasma insulin concentrations during the
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point 105 min) and 721 pM (at time point 120 min)
during this clamp.
Discussion
With the present case we report, to our knowledge,
unprecedented high plasma insulin (13,770 pM) and C-
peptide concentrations (22,380 pM) in a healthy subject.
Maximum beta cell secretory capacity has been inves-
tigated intensively with the aim of describing beta cell
dysfunction in type 2 diabetes. Several tests have been
designed to evaluate this parameter including meal tests,
the glucagon test [11], the hyperglycaemic clamp test
(with or without arginine) and tests combining glucose
and non-glucose stimuli such as arginine and GLP-1
[12]. The highest insulin and C-peptide concentrations
in healthy subjects reported hitherto were elicited by a
test designed to evaluate distinct patterns of insulin
secretion including maximal beta cell secretory capacity
[12]. This design by Fritsche et al. involved a 200 min
10 mM-hyperglycaemic clamp with continuous iv infusion
of GLP-1 (1.5 pmol/kg/min) starting at 120 min and an
arginine bolus of 5 g at 180 min performed in 7 healthy
volunteers. Following the arginine bolus mean peak
concentrations of insulin and C-peptide amounted to
8,495 pM (±1499 pM, standard error of the mean) and
14,729 ± 1863 pM, respectively. These responses exceeded
those seen following arginine given as a bolus during
hyperglycaemic conditions (>25 mM glucose) - a test often
considered to provoke the maximal insulin response
[13] - by more than 100%. Interestingly, the immense beta
cell secretory responses in this report and the responses
reported by Fritsche et al. occurred with a continuous
GLP-1 stimulus during hyperglycaemic conditions. Fur-
thermore, there were no signs indicating that the beta cell
response in our subject or the responses in the study by
Fritsche et al. were about to level off towards the end of
the hyperglycaemic clamps. Actually, at that point, the
insulin curves increased steadily (almost exponentially in
the present case). There is no doubt that among the tests
used in the present case the 15 mM-hyperglycaemic clamp
with concomitant infusion of GLP-1 is the strongest
stimulus of beta cell secretion.
What is GLP-1 and how come it is so potent a stimulator
of glucose-induced insulin secretion? GLP-1 is a product
of the proglucagon gene [14] that, when expressed in
mucosal enteroendocrine L cells is processed by prohor-
mone convertase 1/3 to GLP-1, glucagon-like peptide-2 (a
key regulator of small intestinal growth) and glicentin. The
other incretin hormone GIP is a 42 amino acid-peptide
processed (also by prohormone convertase 1/3) from a
precursor of 153 amino acids [15] in mucosal enteroendo-
crine K cells. GLP-1 and GIP are secreted in response to
ingestion of nutrients, with lipids and simple carbohydratesbeing potent stimulators of secretion [1]. In the present
case the endogenous incretin hormone responses were
evaluated during a meal test (day 1) and the subject exhib-
ited postprandial responses within the normal range.
Specific receptors of GLP-1 and GIP, both belonging
to the glucagon subfamily of type 2 G protein-coupled
receptors, are found in the pancreatic beta cell plasma
membrane [2]. Following binding and subsequent activa-
tion of adenylate cyclase, intracellular accumulation of
cAMP, closure of ATP sensitive K+-channels (K-ATP
channels) and elevation of cytosolic Ca++ concentrations,
mobilisation and exocytosis of insulin containing gran-
ules occur [16]. These molecular signalling mechanisms
are very similar for the two receptors.
In the present design the doses of incretin hormones
used during the hyperglycaemic clamp experiments (1
pmol GLP-1/kg/min and 4 pmol GIP/kg/min) were chosen
to obtain maximum beta cell stimulation without causing
side effects such as nausea. As illustrated in the insert of
Figure 2 these two supraphysiological stimuli resulted in
similar first-phase insulin responses (AUC0–10 min) whereas
the second-phase insulin response (AUC10–120 min) with
concomitant GLP-1 infusion was almost 6 times greater
as compared to the response during concomitant GIP
infusion, which did not induce the same exponential
rise in insulin secretion as GLP-1. Thus, it seems likely
that the mechanistic differences in the insulinotropic
power of the two incretin hormones take place during
the second-phase insulin response. The mechanisms
underlying the second-phase insulin response have been
suggested to be due to a signal generated by the K-ATP
channel-independent pathway (amplifying pathway) and
requires that the beta cell replaces released docked
granulas from a reserve pool followed by preparation
for exocytosis [17]. The present results suggest that
GLP-1 and GIP differ in relation to the effect on the
insulin secretory machinery in the beta cell. It is well-
established that both GIP and GLP-1 stimulate insulin
biosynthesis [4], and thereby provides supplies of insu-
lin for secretion. Additionally GLP-1 may also stimulate
second-phase insulin secretion by other means. The
abovementioned accumulation of cAMP and closure of
K-ATP channels upon stimulation of the GLP-1 recep-
tor and the GIP receptor, respectively, is related to the
activation of protein kinase A, which decreases the
stimulatory action of ADP at the K-ATP channels. Also,
cAMP may act via Epac2 to increase the inhibitory
action of ATP at the channel [18], and furthermore,
some evidence suggests that cAMP affects K-ATP channel
function by up-regulating glucose-dependent mitochondrial
ATP production and thereby closing the K-ATP channels
[19]. If the GLP-1 receptor is coupled to all of these three
pathways, and the GIP receptor is coupled to only one or
two, it would explain the superior insulinotropic potency of
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cAMP-elevating agents. Obviously these are speculations
that need to be tested mechanistically.
Conclusion
Here we report unprecedented high plasma insulin and
C-peptide responses (elicited by iv infusion of GLP-1
during hyperglycaemia) in a healthy subject, and propose
potential mechanistic differences underlying the differ-
ential insulinotropic effects of the two incretins.
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